Fresh Air His Cancer Meds Were Nearly $1K A Pill. How Did That Happen?
30 snips
May 14, 2025 
David Armstrong, a Senior reporter for ProPublica, dives into the troubling world of the pharmaceutical industry, spotlighting the exorbitant cost of the cancer drug Revlimid. He discusses how this $1,000-a-pill treatment only costs a mere 25 cents to produce. Armstrong reveals the devious strategies companies employ to maintain high prices and fend off competitors. He also sheds light on the hurdles patients face with insurance denials for necessary treatments, exposing the systemic flaws in the healthcare system.
AI Snips
Chapters
Books
Transcript
Episode notes
Armstrong's Myeloma Diagnosis Story
- David Armstrong's multiple myeloma began with unrelenting side pain and worsened until he couldn't get out of bed.
- His diagnosis came with discovering bone damage from the disease, which is often found after bone fractures.
Myeloma Survival Improved
- Drug advances like Revlimid have transformed multiple myeloma into a chronic disease for many.
- Survival times have extended from a few years to many more due to multiple treatment options.
Persistence Yields a Breakthrough
- Beth Wollmer persistently researched thalidomide despite its notorious history.
- Her efforts led to promising multiple myeloma treatment results in Arkansas, sparking hope.
